These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

697 related items for PubMed ID: 19375360

  • 21. Nephrogenic systemic fibrosis: a gadolinium-associated fibrosing disorder in patients with renal dysfunction.
    Kay J.
    Ann Rheum Dis; 2008 Dec; 67 Suppl 3():iii66-9. PubMed ID: 19022818
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Nephrogenic systemic fibrosis and the role of gadolinium contrast media.
    van der Molen AJ.
    J Med Imaging Radiat Oncol; 2008 Aug; 52(4):339-50. PubMed ID: 18811757
    [Abstract] [Full Text] [Related]

  • 26. Gadolinium-based contrast agents and NSF: evidence from animal experience.
    Sieber MA, Steger-Hartmann T, Lengsfeld P, Pietsch H.
    J Magn Reson Imaging; 2009 Dec; 30(6):1268-76. PubMed ID: 19938039
    [Abstract] [Full Text] [Related]

  • 27. How to avoid nephrogenic systemic fibrosis: current guidelines in Europe and the United States.
    Thomsen HS.
    Radiol Clin North Am; 2009 Sep; 47(5):871-5, vii. PubMed ID: 19744601
    [Abstract] [Full Text] [Related]

  • 28. Nephrogenic systemic fibrosis and contrast medium-induced nephropathy: a choice between the devil and the deep blue sea for patients with reduced renal function?
    Lind Ramskov K, Thomsen HS.
    Acta Radiol; 2009 Nov; 50(9):965-7. PubMed ID: 19863403
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Involvement of gadolinium chelates in the mechanism of nephrogenic systemic fibrosis: an update.
    Idée JM, Port M, Dencausse A, Lancelot E, Corot C.
    Radiol Clin North Am; 2009 Sep; 47(5):855-69, vii. PubMed ID: 19744600
    [Abstract] [Full Text] [Related]

  • 32. Patient characteristics and risk factors for nephrogenic systemic fibrosis following gadolinium exposure.
    Grobner T, Prischl FC.
    Semin Dial; 2008 Sep; 21(2):135-9. PubMed ID: 18226001
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Update on nephrogenic systemic fibrosis.
    Thomsen HS, Marckmann P, Logager VB.
    Magn Reson Imaging Clin N Am; 2008 Nov; 16(4):551-60, vii. PubMed ID: 18926421
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Gadolinium and nephrogenic systemic fibrosis: have we overreacted?
    Penfield JG, Reilly RF.
    Semin Dial; 2011 Nov; 24(5):480-6. PubMed ID: 21913988
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 35.